Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000633973 | SCV000755246 | uncertain significance | Gastrointestinal stromal tumor; Paragangliomas 4; Pheochromocytoma | 2024-09-30 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 2 of the SDHB protein (p.Ala2Val). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with SDHB-related conditions. ClinVar contains an entry for this variant (Variation ID: 528745). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on SDHB protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Center for Genomic Medicine, |
RCV002268223 | SCV002552296 | uncertain significance | not specified | 2025-03-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002358781 | SCV002656151 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-11-13 | criteria provided, single submitter | clinical testing | The p.A2V variant (also known as c.5C>T), located in coding exon 1 of the SDHB gene, results from a C to T substitution at nucleotide position 5. The alanine at codon 2 is replaced by valine, an amino acid with similar properties. This alteration was detected in a 49 year old female with a prolactin pituitary adenoma, primary hyperparathyroidism, and parathyroid tumor tissue that demonstrated preserved staining for SDHA and SDHB immunohistochemistry. The family history included an aunt with Cushing's disease; however, there was no known family history of paraganglioma or pheochromocytoma (De Sousa SMC et al. Eur J Endocrinol, 2017 May;176:635-644). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
All of Us Research Program, |
RCV004003831 | SCV004832808 | uncertain significance | Hereditary pheochromocytoma-paraganglioma | 2023-06-26 | criteria provided, single submitter | clinical testing | This missense variant replaces alanine with valine at codon 2 of the SDHB protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with hereditary pituitary adenoma syndrome (PMID: 28220018). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Baylor Genetics | RCV004568393 | SCV005056646 | uncertain significance | Gastrointestinal stromal tumor | 2023-12-19 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV005000408 | SCV005624031 | uncertain significance | not provided | 2024-03-11 | criteria provided, single submitter | clinical testing |